Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16944278rdf:typepubmed:Citationlld:pubmed
pubmed-article:16944278lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:16944278lifeskim:mentionsumls-concept:C0026809lld:lifeskim
pubmed-article:16944278lifeskim:mentionsumls-concept:C0021270lld:lifeskim
pubmed-article:16944278lifeskim:mentionsumls-concept:C0600688lld:lifeskim
pubmed-article:16944278lifeskim:mentionsumls-concept:C0205217lld:lifeskim
pubmed-article:16944278lifeskim:mentionsumls-concept:C0679109lld:lifeskim
pubmed-article:16944278lifeskim:mentionsumls-concept:C0047640lld:lifeskim
pubmed-article:16944278pubmed:issue5lld:pubmed
pubmed-article:16944278pubmed:dateCreated2006-9-14lld:pubmed
pubmed-article:16944278pubmed:abstractTextGlutaric acidaemia type I (GA I) is an inborn error of metabolism caused by a deficiency of glutaryl-CoA dehydrogenase (GCDH) and is characterized clinically by striatal degeneration that almost always occurs in early childhood. A murine knockout model of GA I has the organic aciduria seen in the human disorder, but this model does not develop striatal degeneration spontaneously. 3-Nitropropionic acid (3NP), a succinic dehydrogenase inhibitor with specificity for the striatum, was investigated as a potential initiator of striatal degeneration in GCDH-deficient mice. This study shows that GCDH-deficient mouse pups are more susceptible to 3NP than their wild-type littermates, and that all mouse pups are more sensitive to 3NP as infants than as adolescents and adults. Increased sensitivity to 3NP early in life may model the developmental window for the striatal damage observed in human GA I.lld:pubmed
pubmed-article:16944278pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16944278pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16944278pubmed:languageenglld:pubmed
pubmed-article:16944278pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16944278pubmed:citationSubsetIMlld:pubmed
pubmed-article:16944278pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16944278pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16944278pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16944278pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16944278pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16944278pubmed:statusMEDLINElld:pubmed
pubmed-article:16944278pubmed:monthOctlld:pubmed
pubmed-article:16944278pubmed:issn0141-8955lld:pubmed
pubmed-article:16944278pubmed:authorpubmed-author:GoodmanS ISIlld:pubmed
pubmed-article:16944278pubmed:authorpubmed-author:FreedC RCRlld:pubmed
pubmed-article:16944278pubmed:authorpubmed-author:CrnicL SLSlld:pubmed
pubmed-article:16944278pubmed:authorpubmed-author:BjugstadK BKBlld:pubmed
pubmed-article:16944278pubmed:issnTypePrintlld:pubmed
pubmed-article:16944278pubmed:volume29lld:pubmed
pubmed-article:16944278pubmed:ownerNLMlld:pubmed
pubmed-article:16944278pubmed:authorsCompleteYlld:pubmed
pubmed-article:16944278pubmed:pagination612-9lld:pubmed
pubmed-article:16944278pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:16944278pubmed:meshHeadingpubmed-meshheading:16944278...lld:pubmed
pubmed-article:16944278pubmed:meshHeadingpubmed-meshheading:16944278...lld:pubmed
pubmed-article:16944278pubmed:meshHeadingpubmed-meshheading:16944278...lld:pubmed
pubmed-article:16944278pubmed:meshHeadingpubmed-meshheading:16944278...lld:pubmed
pubmed-article:16944278pubmed:meshHeadingpubmed-meshheading:16944278...lld:pubmed
pubmed-article:16944278pubmed:meshHeadingpubmed-meshheading:16944278...lld:pubmed
pubmed-article:16944278pubmed:meshHeadingpubmed-meshheading:16944278...lld:pubmed
pubmed-article:16944278pubmed:meshHeadingpubmed-meshheading:16944278...lld:pubmed
pubmed-article:16944278pubmed:meshHeadingpubmed-meshheading:16944278...lld:pubmed
pubmed-article:16944278pubmed:meshHeadingpubmed-meshheading:16944278...lld:pubmed
pubmed-article:16944278pubmed:meshHeadingpubmed-meshheading:16944278...lld:pubmed
pubmed-article:16944278pubmed:meshHeadingpubmed-meshheading:16944278...lld:pubmed
pubmed-article:16944278pubmed:meshHeadingpubmed-meshheading:16944278...lld:pubmed
pubmed-article:16944278pubmed:meshHeadingpubmed-meshheading:16944278...lld:pubmed
pubmed-article:16944278pubmed:meshHeadingpubmed-meshheading:16944278...lld:pubmed
pubmed-article:16944278pubmed:year2006lld:pubmed
pubmed-article:16944278pubmed:articleTitleInfant mice with glutaric acidaemia type I have increased vulnerability to 3-nitropropionic acid toxicity.lld:pubmed
pubmed-article:16944278pubmed:affiliationDepartment Psychiatry, University of Colorado Health Sciences Center, Denver, Colorado, USA. Kimberly.Bjugstad@UCHSC.edulld:pubmed
pubmed-article:16944278pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16944278pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:16944278pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed